Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

Research and development expenses for the third quarter of 2009 decreased to $1.5 million from $1.6 million in 2008, due mainly to lower costs associated with OGX-427. For the nine months ended September 30, 2009 research and development expenses increased to $6.8 million from $3.6 million in 2008. The increase was primarily due to OGX-011 and OGX-427 manufacturing-related costs incurred in the first nine months of 2009, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first nine months of 2008 was a Scientific Research and Development (SRED) claim, which offset R&D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company as a result of the reverse takeover, SRED claims can now only be applied against taxes payable.

General and administrative expenses for the third quarter decreased to $0.9 million from $1.0 million in 2008, due mainly to lower legal and accounting fees incurred in 2009. For the nine months ended S
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Washington, USA (PRWEB) September 30, 2014 ... yet efficient arrangements that have evolved in nature over ... biomimetic and bioinspired materials for applications in biophotonics ... Biomedical Optics . The journal is published by SPIE, ... SPIE Digital Library. Several of the peer-reviewed articles are ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 The U.S. ... to Southern Illinois University Edwardsville as part of the ... initiative. The funding is co-administered by the Department of ... Biden, Secretary of Labor Thomas E. Perez and Secretary ... million in job-driven training grants to nearly 270 colleges ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Protocol combines benefits of TRI Reagent , ... isolation , technology , ... flash-frozen, or RNAlater-treated tissues , ... throughput processing using multichannel pipettes or automated ...
... A variety of siRNA ... screening, require the efficient delivery of , ... studies describe performing transfections in 6 well and 24 , ... NeoFX Transfection Agent ...
... siRNA Electroporation Kit , , ... Deliver siRNA into primary cells, , ... cells , Maintain high cell viability under a wide , ... cells quickly with included positive and negative ...
Cached Biology Technology:High Throughput RNA Isolation for High Performance Microarray Analysis 2High Throughput RNA Isolation for High Performance Microarray Analysis 3High Throughput RNA Isolation for High Performance Microarray Analysis 4High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 2High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 3High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 4High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 5High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 6High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 7High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 8High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 9High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 10Deliver siRNAs Into Primary Cells 2Deliver siRNAs Into Primary Cells 3Deliver siRNAs Into Primary Cells 4Deliver siRNAs Into Primary Cells 5Deliver siRNAs Into Primary Cells 6
(Date:10/1/2014)... Soil microbes that thrive in the deserts, rainforests, prairies ... living beneath New York City,s Central Park, according to ... and the University of Colorado Boulder. , The ... Central Park,s 843 acres and discovered a stunning diversity ... documented before. , Only 8.5 percent to 16.2 ...
(Date:9/30/2014)... the University of California, San Diego, have completed the ... a method that uses the pixels in an image ... as mesh-free simulation. , The researchers, led by J.S. ... the Jacobs School of Engineering at UC San Diego, ... at the CompIMAGE,14 conference in Pittsburgh this month. Chen ...
(Date:9/30/2014)... watermelon, salmon, and strawberries all have in common? ... of chromosomes and are diploid, these organisms are all ... chromosomesseedless watermelon and salmon have 3 and 4 sets ... this might seem surprising, in fact most plant species ... over a century ago, but only recently, with the ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4
... Wheat plants found to be resistant to Hessian fly ... rigid defenses. Christie Williams, a research scientist with ... a Purdue University associate professor of entomology, found that ... production of surface waxes and cutin, a molecule responsible ...
... physically weaker as they age? And is there any way ... link between increasing age and frailty? In a ... Clinical Endocrinology & Metabolism , University of Texas Medical Branch ... questions can be found in the way the network of ...
... power of synchrotron light to Minnesota,s academic and industrial ... of Agreement (MOA) signed today between the BioBusiness Alliance ... Canadian Light Source (CLS). "The goal of ... while improving operating efficiency for both Minnesota and Canadian ...
Cached Biology News:Resistant wheat rebuilds cell walls when attacked by Hessian flies 2Muscle loss in elderly linked to blood vessels' failure to dilate 2BioBusiness Alliance, Canadian Light Source Synchrotron sign agreement 2
... Special optically clear polystyrene formulation , ... immunoassay applications , Plates are certified ... of variation , Eight-well strips fit ... loss while in use even if turned ...
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Lipid adsorption and clarification reagent; Ideal ... purification of antibodies, proteins, nucleic acids, ... negligible cross-reactivity, and improves downstream processing; ... solid-phase, non-ionic adsorbent supplied as a ...
Biology Products: